An interventional study of Educational Intervention and Survey Administration in Lung Carcinoma, sponsored by Fred Hutchinson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 50 Years to 77 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Fred Hutchinson Cancer Center · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center — 6 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Fred Hutchinson Cancer Center.
Among the 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2026, is one of 8 with no phase, and was the 11th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →6 of the 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center are open now, in 2 countries. Recruiting first, the newest first:
Fred Hutchinson Cancer Center · Sites in United States
Ages 50–80 · Healthy volunteers
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
Fred Hutchinson Cancer Center · Sites in Uganda
Ages 18+
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 50 Years to 77 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 4 1
First in 1985; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 52 across the 12 interventional studies, 102 across the 1 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fred Hutchinson Cancer Center is the lead sponsor of 547 studies on the registry; 79 are open to participants now.
Of its 59 completed or terminated interventional studies of FDA-regulated products, 46 (78%) have results posted.
4 of the studies in Lung Neoplasms by Fred Hutchinson Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07490860Fred Hutchinson Cancer CenterA Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial | 2026-12-31 |
| NCT07615764Fred Hutchinson Cancer CenterAn Educational Intervention (Lung Toolkit) for Improving Knowledge About Lung Cancer and Screening Among American Indian and Alaskan Native Cigarette Smokers, Lung PATHS Trial | 2027-03-31 |
| NCT06324110Fred Hutchinson Cancer CenterEvaluating the Impact of Centralized Interventions on Lung Cancer Screening Adherence in Community Settings, ACCELL Trial | 2027-10-31 |
| NCT05098210Fred Hutchinson Cancer CenterPersonalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer | 2027-11-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial develops and studies whether a restorative justice-based lung cancer screening (LCS) decision-making support intervention tailored for Black individuals increases LCS among Black community members. Lung cancer remains the leading cause of cancer deaths among Black men and women. LCS with yearly low-dose chest computed tomography (CT) is recommended for people with current or recent tobacco use (within 15 years) who are aged 50-80 with at least a 20 pack-year smoking history. LCS lowers lung cancer death by 20%; however, data shows that LCS completion remains low among minority groups in the United States. The restorative justice-based LCS decision-making support intervention in this trial has been specifically tailored to meet the needs of Black individuals. It is designed to reduce racial unfairness by promoting trust, shared understanding, and empowerment in clinical decision making while addressing the social and historical circumstances of health inequalities. This may be an effective way to increase LCS among Black community members.
OUTLINE:
Participants attend an in-person restorative justice-based LCS decision-making support session over 2-3 hours on study.
After completion of study intervention, participants may be followed up at 90 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants attend an in-person restorative justice-based LCS decision-making support session over 2-3 hours on study.
Other: Educational Intervention · Other: Survey Administration · Other: Interview · Other: Electronic Health Record Review
Attend LCS decision-making support session
Ancillary studies
Ancillary studies
Ancillary studies
Intervention acceptability
Assessed using the Acceptability of Intervention Measure (AIM). The AIM will be summarized and presented as a range of scores from 1 (low acceptability/appropriateness) to 5 (high acceptability/appropriateness).
Time frame: At post-intervention (Day 1)
Lung cancer screening knowledge
Will be assessed using the Lung Cancer Screening Knowledge 7 question score. Pre- and post-intervention responses will be compared via Chochran-Mantel-Haenszel and Friedman tests.
Time frame: At pre- and post-intervention (both on Day 1)
Readiness to screen
Will be assessed using the Lung Cancer Screening Health Belief Scales. Participant responses will be summarized with the median and range of scores at pre- and post-intervention.
Time frame: At pre- and post-intervention (both on Day 1)
Medical mistrust
Will be assessed using the Discrimination in Medical Setting and Group-Based Medical Mistrust scale. Participant responses will be summarized with the median and range of scores at pre- and post-intervention.
Time frame: At pre- and post-intervention (both on Day 1)
Perceived smoking-related stigma
Will be assessed using the Cataldo Lung Cancer Stigma Scale: smoking-related subscale. Participant responses will be summarized with the median and range of scores at pre- and post-intervention.
Time frame: At pre- and post-intervention (both on Day 1)
Shared decision-making (SDM) process
Will be assessed using the Shared Decision Making Questionnaire. Participant responses will be summarized with the median and range of scores, with 0 indicating no SDM behavior and 100 indicating ideal SDM behavior.
Time frame: At post-intervention (Day 1)
Completion of chest computed tomography (CT)
Will assess completion of chest CT within 90 days post-intervention with no comparison.
Time frame: Up to 90 days post-intervention
Intervention acceptability and refinement
Will recruit a subset of participants to participate in a semi-structured interview post-intervention to gain an in-depth understanding of intervention acceptability and intervention refinement, including participant perspectives about the integration of restorative justice-based lung cancer screening decision-making support. Qualitative interview data will be analyzed using a mixed inductive-deductive approach to thematic analysis.
Time frame: At 90 days post-intervention
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2026, 0 months later.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 0 months is below that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fred Hutchinson Cancer Center →